Literature DB >> 15052500

Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis.

Katie Forbes1, Karin Gillette, Laura A Kelley, Inder Sehgal.   

Abstract

To understand alterations to the urokinase system that may occur in progressively metastatic prostate cancer cells, we assessed urokinase plasminogen activator receptor (uPAR) expression, in vitro motility towards vitronectin, urokinase plasminogen activator (uPA)-induced growth and growth factor regulation of uPAR expression in three cell lines--PC-3 and two derivatives from secondary metastases, PC-3M and PC-3MM2. DU-145 and Tsu-Pr1 cells were included for comparative purposes. uPAR expression increases with metastatic passage in these cell lines and accompanies increased growth and motility responses in the presence of uPA. Growth factors TGFbeta1 and IGF-1 induce uPAR in all three prostate cancer lines; however, PC-3M and PC-3MM2 cells also respond to bFGF. Of the cell lines tested, PC-3MM2 most uniformly respond to added TGFbeta1, IGF-1 and bFGF. These results show that in two progressive derivatives from repeated metastasis of PC-3 cells, constitutive and growth factor-induced uPAR expression is enhanced. This increased uPAR facilitates the properties of growth and motility.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15052500     DOI: 10.1007/s00345-003-0395-3

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  19 in total

1.  Prostate cancer in bone: importance of context for inhibition of matrix metalloproteinases.

Authors:  Mina J Bissell; Johanne Le Beyec; Robin L Anderson
Journal:  J Natl Cancer Inst       Date:  2002-01-02       Impact factor: 13.506

2.  Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique.

Authors:  G F Greene; Y Kitadai; C A Pettaway; A C von Eschenbach; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.

Authors:  H Biliran; S Sheng
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

4.  Reduced secretion of MMPs, plasminogen activators and TIMPS from prostate cancer cells derived by repeated metastasis.

Authors:  Inder Sehgal; Katie Forbes; Matthew A Webb
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

5.  Systemic administration of 4-amidinoindanon-1-(2'-amidino)-hydrazone, a new inhibitor of s-adenosylmethionine decarboxylase, produces cytostasis of human prostate-cancer in athymic nude-mice.

Authors:  M Delworth; K Nishioka; C Pettaway; M Gutman; J Killion; A Voneschenbach; I Fidler
Journal:  Int J Oncol       Date:  1995-02       Impact factor: 5.650

6.  The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.

Authors:  C P Webb; C D Hose; S Koochekpour; M Jeffers; M Oskarsson; E Sausville; A Monks; G F Vande Woude
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

Review 7.  Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.

Authors:  S A Rabbani; R H Xing
Journal:  Int J Oncol       Date:  1998-04       Impact factor: 5.650

8.  The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.

Authors:  G Høyer-Hansen; N Behrendt; M Ploug; K Danø; K T Preissner
Journal:  FEBS Lett       Date:  1997-12-22       Impact factor: 4.124

9.  Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines.

Authors:  W Hollas; N Hoosein; L W Chung; A Mazar; J Henkin; K Kariko; E S Barnathan; D Boyd
Journal:  Thromb Haemost       Date:  1992-12-07       Impact factor: 5.249

10.  Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.

Authors:  C A Pettaway; S Pathak; G Greene; E Ramirez; M R Wilson; J J Killion; I J Fidler
Journal:  Clin Cancer Res       Date:  1996-09       Impact factor: 12.531

View more
  6 in total

1.  Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.

Authors:  Andrew P Mazar; Richard W Ahn; Thomas V O'Halloran
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

2.  Prostate cancer cell surface-associated keratin 8 and its implications for enhanced plasmin activity.

Authors:  Melissa Hirsch Kuchma; Joo Hee Kim; Mark T Muller; Philip A Arlen
Journal:  Protein J       Date:  2012-03       Impact factor: 2.371

3.  Long term increased expression of the short form 1b prolactin receptor in PC-3 human prostate cancer cells decreases cell growth and migration, and causes multiple changes in gene expression consistent with reduced invasive capacity.

Authors:  Kuang-tzu Huang; Ameae M Walker
Journal:  Prostate       Date:  2010-01-01       Impact factor: 4.104

4.  Prostate cancer cells show elevated urokinase receptor in a mouse model of metastasis.

Authors:  Inder Sehgal; Timothy P Foster; Joseph Francis
Journal:  Cancer Cell Int       Date:  2006-08-23       Impact factor: 5.722

5.  The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells.

Authors:  Danielle Lejeune; Mohammad Hasanuzzaman; Amanda Pitcock; Joseph Francis; Inder Sehgal
Journal:  Mol Cancer       Date:  2006-06-06       Impact factor: 27.401

6.  A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines.

Authors:  Mohammad Hasanuzzaman; Robert Kutner; Siamak Agha-Mohammadi; Jakob Reiser; Inder Sehgal
Journal:  Mol Cancer       Date:  2007-05-17       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.